Biofrontera AG (NASDAQ:BFRA) is reporting second quarter earnings results on Wednesday 26th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.16 per share from $ 7.90 million in revenue.
For the full year, analysts predict revenues of $ 26.70 million, while looking forward to loss of $ 1.09 per share.
Previous Quarter Performance
Biofrontera AG disclosed loss for the first quarter of $ 0.15 per share, from the revenue of $ 7.14 million. Street analysts expected Biofrontera AG to report loss of $ 0.34 per share on revenue of $ 7.00 million for the first quarter. The bottom line results beat street analysts by $ 0.19 or 55.88 percent, at the same time, top line results outshined analysts by $ 0.14 million or 2.00 percent.
Stock Performance
Shares of Biofrontera AG traded low $ -0.33 or -3.16 percent on Tuesday, reaching $ 10.11 with volume of 130.40 thousand shares. The stock opened down for the day at $ 10.33, after closing the previous day trading at $ 10.44.
According to the previous trading day, closing price of $ 10.44, representing a 98.10 % increase from the 52 week low of $ 5.27 and a 81.02 % decrease over the 52 week high of $ 55.00.
The company has a market capital of $ 226.47 million and is part of the Healthcare sector and Biotechnology industry.
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
